Article Details

Incyte, Novartis aim to make Jakafi available in severe COVID-19 after narrow trial miss

Retrieved on: 2021-03-19 15:33:45

Tags for this article:

Click the tags to see associated articles and topics

Incyte, Novartis aim to make Jakafi available in severe COVID-19 after narrow trial miss. View article details on hiswai:

Excerpt

Meanwhile, newly developed monoclonal antibodies, including those from Eli Lilly and Regeneron, are now authorized to treat the disease. In addition ...

Article found on: www.fiercepharma.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up